The Online Investor
Forte Biosciences Inc (TOCA)

Tocagen is a clinical-stage, cancer-selective gene therapy company focused on developing product candidates designed to activate a patient's immune system against their own cancer. Co.'s cancer-selective gene therapy platform is built on Retroviral Replicating Vectors, which are designed to selectively deliver therapeutic genes into the DNA of cancer cells. Co.'s gene therapy approach is designed to fight cancer through immunotherapeutic mechanisms of action without the autoimmune toxicities commonly experienced with other immunotherapies.
Company Name: 
Forte Biosciences Inc
Website: 
www.tocagen.com
Sector: 
Drugs & Pharmaceuticals
Quotes delayed 20 minutes

Email EnvelopeFree TOCA Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Hold (2.00 out of 4)
100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Forte Biosciences Inc (TOCA) Page | The Online Investor Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2024, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.